Genor Biopharma faces further delay in circular despatch

Genor Biopharma Holdings [HKEX:6998] faces a further delay in despatching its circular concerning a major acquisition and reverse takeover, as disclosed on June 26, 2025. The circular, initially announced on October 7, 2024, involves a substantial acquisition with consideration shares, a reverse takeover requiring a new listing application, and related matters, including a whitewash waiver application, personnel retention plan, name change, share capital increase, and a share option plan. The despatch, already delayed, is now expected by October 31, 2025, due to ongoing regulatory feedback. Concurrently, Genor Biopharma announced the results of its AGM held on June 26, 2025, where all proposed resolutions were passed. These included adopting the audited financial statements, re-electing executive and non-executive directors, and re-appointing Ernst & Young as auditor. Additionally, Dr. Lyu Dong retired as non-executive Director, and Ms. Cui Bai joined the Nomination Committee. Shareholders are cautioned that the merger's completion and the new listing application's approval are uncertain, advising careful share trading.